Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44

Tajima,Hidehiro; Ohta,Tetsuo; Kitagawa,Hirohisa; Okamoto,Koichi; Sakai,Seisho; Kinoshita,Jun; Makino,Isamu; Furukawa,Hiroyuki; Hayashi,Hironori; Nakamura,Keishi; Oyama,Katsunobu; Inokuchi,Masafumi; Nakagawara,Hisatoshi; Fujita,Hideto; Takamura,Hiroyuki; Ninomiya,Itasu; Fushida,Sachio; Tani,Takashi; Fujimura,Takashi; Kitamura,Seiko; Ikeda,Hiroko; Tsuneyama,Koichi

doi:10.3892/ol.2012.657

Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44

Authors:
- Hidehiro Tajima
- Tetsuo Ohta
- Hirohisa Kitagawa
- Koichi Okamoto
- Seisho Sakai
- Jun Kinoshita
- Isamu Makino
- Hiroyuki Furukawa
- Hironori Hayashi
- Keishi Nakamura
- Katsunobu Oyama
- Masafumi Inokuchi
- Hisatoshi Nakagawara
- Hideto Fujita
- Hiroyuki Takamura
- Itasu Ninomiya
- Sachio Fushida
- Takashi Tani
- Takashi Fujimura
- Seiko Kitamura
- Hiroko Ikeda
- Koichi Tsuneyama
View Affiliations

Affiliations: Department of Gastroenterologic Surgery Division of Cancer Medicine, Graduate School of Medicine Science, Kanazawa University, Kanazawa, Japan, Division of Pathology, Kanazawa University Hospital, Kanazawa, Japan, Division of Pathology, Toyama University Hospital, Toyama, Japan
Published online on: March 26, 2012 https://doi.org/10.3892/ol.2012.657
Pages: 1186-1190

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We examined the pathological effects of preoperative neoadjuvant chemotherapy (NAC) and the expression of markers of apoptosis, epithelial-to-mesenchymal transition (EMT) and cancer stem cells in resected pancreatic cancer specimens from patients treated with gemcitabine as NAC. Immunohistochemical expression of the apoptosis marker M30, EMT marker Snail and stem cell marker CD44 in surgically resected pancreatic cancer specimens were compared between patients treated (NAC group n=13) and not treated (control group n=21) with gemcitabine. In the NAC group, the tumor specimens showed tumor cell injury; however, there was no significant reduction of serosal, retroperitoneal, perineural or vascular invasion, lymph node metastasis or tumor size. The expression frequencies of M30 and CD44 were significantly higher in the NAC group (61.5 and 53.8%) compared to the control group (9.5 and 14.3%); however, no significant difference in Snail expression was noted between the two groups (53.8 versus 42.9%). Gemcitabine induced apoptosis of pancreatic cancer cells in vivo; however, it did not reduce the tumor burden. Moreover, the residual cancer tissues were rich in chemoresistant cancer stem cells. By contrast, marked EMT of cancer cells was observed in the specimens from the groups treated and not treated with gemcitabine.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin. 58:71–96. 2008.
3	Conlon KC, Klimstra DS and Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinico-pathologic analysis of 5-year survivors. Ann Surg. 223:273–279. 1996.PubMed/NCBI
4	Matsuno S, Egawa S, Fukuyama S, et al: Pancreatic cancer registry in Japan: 20 years of experience. Pancreas. 28:219–230. 2004.PubMed/NCBI
5	Kayahara M, Nagakawa T, Ueno K, et al: An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 72:2118–2123. 1993. View Article : Google Scholar : PubMed/NCBI
6	Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
7	Ottle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar
8	Golcher H, Brunner T, Grabenbauer G, et al: Preoperative chemo-radiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. EJSO. 34:756–764. 2008. View Article : Google Scholar : PubMed/NCBI
9	Goses MJ, Dressen RC, Rutten HJ, et al: Prepoerative radio-chemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumors. Ann Oncol. 19:2026–2032. 2008. View Article : Google Scholar : PubMed/NCBI
10	Yang AD, Fan F, Camp ER, et al: Chronic oxaliplatin resistance induces epithelial-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153. 2006. View Article : Google Scholar : PubMed/NCBI
11	Tsukamoto H, Shibata K, Kajiyama H, et al: Irradiation-induced epithelial-mesencymal transition (EMT) related to invasive potential in endometrial carcinoma cells. Gynecol Oncol. 107:500–504. 2007. View Article : Google Scholar : PubMed/NCBI
12	Tajima H, Ohta T, Shoji Y, et al: Expression of epithelial-mesenchymal transition markers in locally recurrent hepatocellular carcinoma after radiofrequency ablation. Exp Therap Med. 1:347–350. 2010. View Article : Google Scholar
13	Shah AN, Summy JM, Zhang J, Park SI, Darikh NU and Gallick GE: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI
14	Yang J, Mani SA, Donaher JL, et al: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117:927–939. 2004. View Article : Google Scholar : PubMed/NCBI
15	Hay ED and Zuk A: Transformations between epithelium and mesenchyme: normal, pathological and experimentally induced. Am J Kidney Dis. 26:678–690. 1995. View Article : Google Scholar : PubMed/NCBI
16	Thiery JP: Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
17	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
18	Kikuta K, Masamune A, Watanabe T, et al: Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun. 403:380–384. 2010. View Article : Google Scholar : PubMed/NCBI
19	Evans DB, Rich TA, Byrd DR, et al: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992. View Article : Google Scholar : PubMed/NCBI
20	Dive C, Smith RA, Garner E, et al: Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer. 102:577–582. 2010. View Article : Google Scholar : PubMed/NCBI
21	Du Z, Qin R, Wei C, et al: Pancreatic cancer cells resistant to chemoradiotherapy rich in ‘stem-cell-like’ tumor cells. Dig Dis Sci. 10:741–750. 2010.PubMed/NCBI
22	Hong SP, Wen J, Bang S, Park S and Song SY: CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 125:2323–2331. 2009. View Article : Google Scholar : PubMed/NCBI
23	Müerköster SS, Werbing V, Koch D, et al: Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma – epigenetic downregulation of caspase. Int J Cancer. 123:1751–1760. 2008.PubMed/NCBI
24	Yin T, Wang C, Liu T, Zhao G, Zha Y and Yang M: Expression of Snail in pancreatic cancer promotes metastasis and chemoresistsance. J Surg Res. 141:196–203. 2007. View Article : Google Scholar : PubMed/NCBI
25	Cauffert B, Mornex F, Bonnetain F, et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cicplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 19:1592–1599. 2008.
26	Van Laethem JL, Hammel P, Mornex F, et al: Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012 /FFCD-9203/GERCOR phase II study. J Clin Oncol. 28:4450–4456. 2010.